Intel Interrupted By Weak Demand and 4 Stock Analyses Buzzing on the Street
Celgene Corporation (NASDAQ:CELG): After speaking with a prominent patent attorney, BMO Capital expects Celgene to win their patent litigation against Natco over the Revlimid generic filing. The firm doesn’t expect a generic version of Revlimid to be approved until 2025 or 2027, and they maintain an Outperform rating on Celgene.
JPMorgan Chase & Co. (NYSE:JPM): CLSA continues to believe JPMorgan’s break-up value is approximately $50 per share. The firm believes the company’s recent restructuring may make a split of their consumer and wholesale businesses easier and noted that Jamie Dimon owns approximately a quarter of a billion in stock. The firm gave shares an Underperform with a $37 price target given the company’s current complexity, high capital requirements, and investors lower valuation multiples for large conglomerates.
Onyx Pharmaceuticals Inc. (NASDAQ:ONXX): Ahead of the launch of their Multiple Myeloma drug, Kyprolis, Baird raised their price target on Onyx Pharmaceuticals Inc. The firm cited bullish survey data that included reception and pricing for the drug. Shares are Outperform rated.
Intel Corporation (NASDAQ:INTC): Due to a weak PC demand that is expected over the next few months, Credit Suisse lowered their estimates for Intel Corporation. Shares remain Outperform rated.
Medivation, Inc. (NASDAQ:MDVN): After the company announced the United States approval of Xtandi, for the treatment of some prostate cancer patients, ThinkEquity increased their target on Medivation, Inc. The firm noted that the price of the drug is higher than expected and they maintain a Buy rating on the firm’s shares.
Don’t Miss: Is Apple’s Stock a BUY at $666?
Are these stocks a buy or sell? Let us help you decide. Check out our Wall St. Cheat Sheet Stock Picker Newsletter now >>